Novartis
Coverage of Novartis in the Nexus archive.
- First Complement Inhibitor Wins Full Approval in IgA Nephropathy
The FDA fully approved iptacopan (Fabhalta), a complement inhibitor, to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of progression. Novartis announced the approval, marking the first complement inhibitor approved for this condition.
- STAT+: Four major biotech updates to catch up on
The article highlights four biotech updates: Medicare proposing cuts to 340B payments, Republicans advocating for diversity in clinical trials, former surgeon general Jerome Adams advising on peptides regulation, and Novartis acquiring Myricx Bio for $1.1 billion to expand its cancer drug development. Anthropic CEO Dario Amodei expresses cautious optimism about AI's role in biotechnology.
- STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
Novartis acquired Myricx Bio for $1.1 billion to advance its antibody-drug conjugate (ADC) pipeline with a novel NMTi payload. Congressional Republicans passed a bill funding the FDA, including a report urging the agency to implement requirements for diversifying clinical trials.
- STAT+: Novartis doubles down on molecular glue strategy
Novartis is expanding its molecular glue strategy, Enliven's leukemia drug shows encouraging early data, and SonoThera raised $125 million for an ultrasound-based gene delivery approach. Medicare drug spending is rising faster than expected due to increased GLP-1 medicine use and the Democrats’ Part D redesign.
- STAT+: Enliven Therapeutics’ leukemia drug shows promise in new study
Enliven Therapeutics' leukemia drug, ELVN-001, achieved a 48% major molecular response rate in patients with chronic myeloid leukemia (CML) at 24 weeks. The drug showed higher efficacy in earlier-stage CML patients and outperformed existing treatments from Novartis and Merck in early-stage study results.
- Platner’s anti-corporate crusade hits awkward snag as receipts tell another story
Maine Senate candidate Graham Platner, known for criticizing corporations like Big Pharma, accepted over $30,000 in donations from lobbyists and executives representing those industries between August 2025 and March. Despite pledging to reject contributions over $200 from healthcare industry affiliates, Platner received $1,000 each from lobbyists working for AbbVie, Novartis, and Moderna, though one donation was later returned.
- Platner’s anti-corporate crusade hits awkward snag as receipts tell another story
Graham Platner, a Maine Senate candidate, faces scrutiny for accepting over $30,000 from lobbyists and executives at major corporations while campaigning against big tech, pharmaceuticals, banks, and defense contractors. Despite pledging to reject contributions over $200 from healthcare industry lobbyists, Platner received $1,000 donations from lobbyists representing AbbVie, Novartis, and Moderna prior to making the pledge.
- String of scientist deaths, vanishings fuels expert talks of shadow ops and silenced secrets: 'Very serious'
A string of deaths and disappearances of high-level U.S. scientists, many involved in nuclear science, space research, and UFO studies, has raised concerns about potential shadow operations or criminal organizations. Experts suggest the individuals may have been targeted for their knowledge or protected due to sensitive investigations.